Bioterrorism is no longer a threat in the United States, but a reality. In 2001, the spread of anthrax spores through the U.S. mail illustrated that deadly agents can be acquired and spread using relatively unsophisticated means. It also highlighted our vulnerability to such attacks and the urgency for preparedness. Vaccine-induced protective immunity to potential bioterror weapons could be one of the most effective biodefense strategies. Most of the biodefense vaccines available have been tailored for military personnel (healthy adults). The civilian population in need of protection, however, includes people of all ages and physical conditions (newborns, infants, immunocompromised and the elderly), who are at greater risk and could become the enemy's sinister targets to inflict more casualties. Clearly, there is an urgent need for safe and effective vaccines for these highly vulnerable groups. We propose to evaluate protective efficacy of a new generation of biodefense vaccines based on attenuated Salmonella as a live vector to mucosally deliver protective antigens from Yersinia pestis and Bacillus anthracis. Our first goal is to determine whether these Salmonella biodefense vaccines are well tolerated and induce long-lasting protective immunity using a neonatal mouse model of immunogenicity that closely resembles the responses in humans. Based on preliminary data, we hypothesize that 1) Salmonella live vectors will be highly immunogenic in newborn mice;and 2) antibody and cell-mediated immunity will be induced despite the presence of maternal antibodies. We also aim to explore the mechanisms involved in the induction of neonatal adaptive immunity to Salmonella and encoded foreign antigens. Although neonatal responses to vaccines are usually feeble and Th2 biased, our preliminary data suggest that Salmonella-based biodefense vaccines can induce potent (adult-like) and balanced Th1/Th2- type responses in newborns despite the presence of maternal antibodies. We hypothesize that this is linked to the the capacity of the bacteria to induce neonatal dendritic cell maturation and T cell activation. This research will be highly relevent to public health as it will enable us to identify biodefense vaccines that can be safe and protect children and infants against bioterror weapons. It will also provide knowledge to better understand the mechanisms mediating neonatal-infant immunity to develop more effectivevaccines to prevent diseases early in life.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Zou, Lanling
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
Schools of Medicine
United States
Zip Code
Mellado-Sanchez, Gabriela; Ramirez, Karina; Drachenberg, Cinthia B et al. (2013) Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. Comp Immunol Microbiol Infect Dis 36:113-28
Pasetti, Marcela F; Simon, Jakub K; Sztein, Marcelo B et al. (2011) Immunology of gut mucosal vaccines. Immunol Rev 239:125-48
Wahid, Rezwanul; Pasetti, Marcela F; Maciel Jr, Milton et al. (2011) Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin Immunol 138:187-200
Ramirez, Karina; Ditamo, Yanina; Galen, James E et al. (2010) Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies. Vaccine 28:6065-75
Ramirez, K; Ditamo, Y; Rodriguez, L et al. (2010) Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol 3:159-71
Baillie, Les W; Huwar, Theresa B; Moore, Stephen et al. (2010) An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine 28:6740-8
Ramirez, Karina; Capozzo, Alejandra V E; Lloyd, Scott A et al. (2009) Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost. J Immunol 182:1211-22
Galen, James E; Chinchilla, Magaly; Pasetti, Marcela F et al. (2009) Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis 199:326-35
Galen, James E; Pasetti, Marcela F; Tennant, Sharon et al. (2009) Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 87:400-12
Baillie, Leslie W J; Rodriguez, Ana L; Moore, Stephen et al. (2008) Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy. Vaccine 26:6083-91